Christian Angermayer Buys 1 Million Shares Of Atai Life, His Own Company

Comments
Loading...

april_2022_psychedelics_ad_-_728x90_-_option_c_1.jpg

Christian Angermayer, founder and chairman of Atai Life Sciences ATAI, told Twitter that he bought 1 million shares of his company.

“Many #biotech stocks are cheap at the moment. In my opinion, Atai Life Sciences AG stands out though for two reasons: the size of the market (unfortunately) & the fact that the compounds historically selected by atai have prior human or anecdotal evidence. Hence I have increased my stake via a capped call of 1m shares as filing today,” he explained on LinkedIn.

At the current stock price, the transaction by Angermayer is around $4 million, a show of trust in the potential of his company. Through his investment firm, Apeiron Investment Group, Angermayer is set on standing by what he wrote last December and “put his money where his mouth is.”

These last few months have been kind to Atai, upping its Compass Pathways CMPS stake from 19.4 to 20.8 percent, and with a positive financial results report for 2021.

ATAI Logo
ATAIATAI Life Sciences NV
$1.307.44%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
33.72
Growth
-
Quality
-
Value
1.34
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In:

Cannabis is evolving—don’t get left behind!

Curious about what’s next for the industry and how to stay ahead in today’s competitive market?

Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.

Secure your spot now before prices go up—this is where the biggest deals and connections happen!

Get your tickets today!